Literature DB >> 21948372

Differential effect of inhibiting MD-2 and CD14 on LPS- versus whole E. coli bacteria-induced cytokine responses in human blood.

D Christiansen1, O L Brekke, J Stenvik, J D Lambris, T Espevik, T E Mollnes.   

Abstract

BACKGROUND: Sepsis is a major world-wide medical problem with high morbidity and mortality. Gram-negative bacteria are among the most important pathogens of sepsis and their LPS content is regarded to be important for the systemic inflammatory reaction. The CD14/myeloid differentiation factor 2 (MD-2)/TLR4 complex plays a major role in the immune response to LPS . The aim of this study was to compare the effects of inhibiting MD-2 and CD14 on ultra-pure LPS - versus whole E. coli bacteria-induced responses.
METHODS: Fresh human whole blood was incubated with upLPS or whole E. coli bacteria in the presence of MD-2 or CD14 neutralizing monoclonal antibodies, or their respective controls, and/or the specific complement-inhibitor compstatin. Cytokines were measured by a multiplex (n = 27) assay. NFκB activity was examined in cells transfected with CD14, MD-2 and/or Toll-like receptors.
RESULTS: LPS-induced cytokine response was efficiently and equally abolished by MD-2 and CD14 neutralization. In contrast, the response induced by whole E. coli bacteria was only modestly reduced by MD-2 neutralization, whereas CD14 neutralization was more efficient. Combination with compstatin enhanced the effect of MD-2 neutralization slightly. When compstatin was combined with CD14 neutralization, however, the response was virtually abolished for all cytokines, including IL-17, which was only inhibited by this combination. The MD-2-independent effect observed for CD14 could not be explained by TLR2 signaling.
CONCLUSION: Inhibition of CD14 is more efficient than inhibition of MD-2 on whole E. coli-induced cytokine response, suggesting CD14 to be a better target for intervention in Gram-negative sepsis, in particular when combined with complement inhibition.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21948372     DOI: 10.1007/978-1-4614-0106-3_14

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  12 in total

1.  STAT1 regulates MD-2 expression in monocytes of sepsis via miR-30a.

Authors:  Yanhong Wang; Tiehua Li; Benquan Wu; Hui Liu; Jinmei Luo; Dingyun Feng; Yunfeng Shi
Journal:  Inflammation       Date:  2014-12       Impact factor: 4.092

Review 2.  Platelets: at the nexus of antimicrobial defence.

Authors:  Michael R Yeaman
Journal:  Nat Rev Microbiol       Date:  2014-06       Impact factor: 60.633

Review 3.  Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.

Authors:  Dimitrios C Mastellos; Despina Yancopoulou; Petros Kokkinos; Markus Huber-Lang; George Hajishengallis; Ali R Biglarnia; Florea Lupu; Bo Nilsson; Antonio M Risitano; Daniel Ricklin; John D Lambris
Journal:  Eur J Clin Invest       Date:  2015-03-09       Impact factor: 4.686

4.  Post challenge inhibition of C3 and CD14 attenuates Escherichia coli-induced inflammation in human whole blood.

Authors:  Kjetil H Egge; Ebbe B Thorgersen; Julie K Lindstad; Anne Pharo; John D Lambris; Andreas Barratt-Due; Tom E Mollnes
Journal:  Innate Immun       Date:  2013-05-13       Impact factor: 2.680

5.  The Role of Lipopolysaccharide Structure in Monocyte Activation and Cytokine Secretion.

Authors:  Rebecca E Plevin; Megan Knoll; Meghan McKay; Saman Arbabi; Joseph Cuschieri
Journal:  Shock       Date:  2016-01       Impact factor: 3.454

6.  Progress and Trends in Complement Therapeutics.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

7.  Differential requirement for c-Jun N-terminal kinase 1 in lung inflammation and host defense.

Authors:  Jos Van der Velden; Yvonne M W Janssen-Heininger; Sivanarayna Mandalapu; Erich V Scheller; Jay K Kolls; John F Alcorn
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

8.  Matrine suppresses expression of adhesion molecules and chemokines as a mechanism underlying its therapeutic effect in CNS autoimmunity.

Authors:  Quan-Cheng Kan; Lin Zhu; Nan Liu; Guang-Xian Zhang
Journal:  Immunol Res       Date:  2013-05       Impact factor: 4.505

9.  Determination of the binding mode for anti-inflammatory natural product xanthohumol with myeloid differentiation protein 2.

Authors:  Weitao Fu; Lingfeng Chen; Zhe Wang; Chengwei Zhao; Gaozhi Chen; Xing Liu; Yuanrong Dai; Yuepiao Cai; Chenglong Li; Jianmin Zhou; Guang Liang
Journal:  Drug Des Devel Ther       Date:  2016-01-27       Impact factor: 4.162

10.  Periodontal CD14 mRNA expression is downregulated in patients with chronic periodontitis and type 2 diabetes.

Authors:  Dustin C Hedgpeth; Xiaoming Zhang; Junfei Jin; Renata S Leite; Joe W Krayer; Yan Huang
Journal:  BMC Oral Health       Date:  2015-11-18       Impact factor: 2.757

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.